Pande & Conde on: Players and Paths for Healthcare Startups

Healthcare Market Landscape and Go-to-Market Strategies

• Core Industry Segments
  • Human health technology development is fundamentally categorized into three areas: enabling drugs, enabling therapies, or enabling diagnostics.
  • Therapies encompass a diverse range of modalities, including chemical compounds, proteins, cells, genes, and software applications.
  • The development chronology is linear but complex, requiring sequential validation through discovery, regulatory approval, payer reimbursement, healthcare system education, and patient adoption.
• Diagnostics: The Laboratory-Developed Test (LDT) Path
  • Diagnostic startups often utilize a less risky initial strategy by developing Laboratory-Developed Tests (LDTs) for CLIA-certified labs rather than seeking immediate FDA approval for in vitro devices.
  • CLIA certification requires passing basic processes to ensure robust data and reproducibility, allowing for faster market entry compared to traditional diagnostic device clearance.
• Therapeutics: Clinical Trial Requirements
  • Therapeutic development mandates a rigorous, lengthy timeline starting with proof of concept in cells and animals, followed by Phase 1, 2, and 3 human clinical trials.
  • This path necessitates securing regulatory agency permission to administer treatments to humans before any commercialization can occur.
• Alternative Revenue Model: Tools for R&D
  • Entrepreneurs can bypass the long regulatory cycles of end-user therapies/diagnostics by selling enabling technologies directly to the R&D industry.
  • The U.S. R&D industry represents a $75 billion annual market, offering a significant revenue opportunity for companies with transformative tools.
  • This strategy allows for non-exclusive licensing across multiple players, maximizing reach without locking out potential customers.
• Case Studies in Tool-Based Success
  • Atomab: A private biotech unicorn valued well north of $1 billion that succeeded by designing monoclonal antibodies; the company captures small upfront fees and significant downstream economics upon validation.
  • Illumina: Created a necessary infrastructure for genomics by making large-scale, cheap, and reliable whole-genome sequencing feasible, becoming an indispensable partner for the research industry.
• Strategic Decision Framework for Founders
  • Go-to-market strategy must be dictated by the specific nature of the technology and the founder's domain expertise.
  • Founders must explicitly determine three critical variables: the specific proof points required, the regulatory approval pathway, and the payer for the solution.
  • Broadly applicable platforms for elucidating disease biology are best suited for partnership models to avoid the need for deep, parallel expertise in every specific disease.
  • Platforms enabling previously impossible drug development capabilities may justify becoming a drug development company rather than a tool provider.